Fennec Pharmaceuticals (TSE:FRX) has released an update.
Fennec Pharmaceuticals has reported a strong start to 2024 with first-quarter net revenues of $25.4 million, buoyed by an $18 million licensing deal with Norgine for the commercialization of PEDMARQSI™ in select international markets. The company has also solidified its cash position, boasting $51 million in reserves, and sees potential for significant market growth following an exclusive amendment specifying PEDMARK®’s unique formulation. These financial and strategic advances position the company favorably in the outpatient oncology sector.
For further insights into TSE:FRX stock, check out TipRanks’ Stock Analysis page.
